OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - AMGEN | Real-time Bid/Ask 04:27:59 2024-05-14 EDT | ||
| 10.82 EUR / 10.94 EUR | +0.37% |
|
| Current month | +36.87% | ||
| 1 month | +48.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 10.77 | -0.65% | 0 |
| 24-05-13 | 10.84 | -3.04% | 0 |
| 24-05-10 | 11.18 | -1.76% | 0 |
| 24-05-09 | 11.38 | +6.45% | 0 |
| 24-05-08 | 10.69 | +4.70% | 0 |
Delayed Quote Börse Stuttgart
Last update May 14, 2024 at 03:52 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | CJ5L5V |
| ISIN | DE000CJ5L5V8 |
| Date issued | 2018-11-05 |
| Strike | 191.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.74 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.97 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.15 € |
| Spread % | 1.37% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
308.4
USD
Average target price
314.6
USD
Spread / Average Target
+2.01%
- Stock Market
- Certificates
- Certificat